We investigated the relationship between gut health, visceral fat dysfunction and metabolic disorders in diet-induced obesity. C57BL/6J mice were fed control or high saturated fat diet (HFD). Circulating glucose, insulin and inflammatory markers were measured. Proximal colon barrier function was assessed by measuring transepithelial resistance and mRNA expression of tight-junction proteins. Gut microbiota profile was determined by 16S rDNA pyrosequencing. Tumor necrosis factor (TNF)-α and interleukin (IL)-6 mRNA levels were measured in proximal colon, adipose tissue and liver using RT-qPCR. Adipose macrophage infiltration (F4/80+) was assessed using immunohistochemical staining. HFD mice had a higher insulin/glucose ratio (P = 0.020) and serum levels of serum amyloid A3 (131%; P = 0.008) but reduced circulating adiponectin (64%; P = 0.011). In proximal colon of HFD mice compared to mice fed the control diet, transepithelial resistance and mRNA expression of zona occludens 1 were reduced by 38% (P<0.001) and 40% (P = 0.025) respectively and TNF-α mRNA level was 6.6-fold higher (P = 0.037). HFD reduced Lactobacillus (75%; P<0.001) but increased Oscillibacter (279%; P = 0.004) in fecal microbiota. Correlations were found between abundances of Lactobacillus (r = 0.52; P = 0.013) and Oscillibacter (r = −0.55; P = 0.007) with transepithelial resistance of the proximal colon. HFD increased macrophage infiltration (58%; P = 0.020), TNF-α (2.5-fold, P<0.001) and IL-6 mRNA levels (2.5-fold; P = 0.008) in mesenteric fat. Increased macrophage infiltration in epididymal fat was also observed with HFD feeding (71%; P = 0.006) but neither TNF-α nor IL-6 was altered. Perirenal and subcutaneous adipose tissue showed no signs of inflammation in HFD mice. The current results implicate gut dysfunction, and attendant inflammation of contiguous adipose, as salient features of the metabolic dysregulation of diet-induced obesity.
Citation: Lam YY, Ha CWY, Campbell CR, Mitchell AJ, Dinudom A, Oscarsson J, et al. (2012) Increased Gut Permeability and Microbiota Change Associate with Mesenteric Fat Inflammation and Metabolic Dysfunction in Diet-Induced Obese Mice. PLoS ONE 7(3): e34233. https://doi.org/10.1371/journal.pone.0034233
Editor: Randy Ren Zhang, Wayne State University, United States of America
Received: December 21, 2011; Accepted: February 24, 2012; Published: March 23, 2012
Copyright: © 2012 Lam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a Project Grant (#633240) from the National Health and Medical Research Council of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: I have read the journal's policy and have the following conflicts: JO and LHS are or have been employed by AstraZeneca. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. The other authors have declared that no competing interests exist.
Visceral adiposity is strongly related to metabolic dysfunction including insulin resistance and systemic inflammation –. The deleterious metabolic effect of visceral fat is a consequence, in large part, of increased production of pro-inflammatory cytokines . Adipose-derived immune factors primarily originate from cells in the stromal-vascular fraction of fat depots , . Specifically, macrophage infiltration has been identified as a major determinant of the metabolic effect of adipose tissue. The abundance of macrophages in visceral fat was negatively correlated with insulin sensitivity of obese individuals, whereas no such relationship was observed with subcutaneous fat . The primary driver of the macrophage infiltration and pro-inflammatory profile of visceral fat, however, remains largely unknown.
Evidence is now persuasive that the gut may play an important role in inducing adipose inflammation and metabolic disorders. In patients with Crohn's disease, the inflamed gut is associated with an expanded mesenteric fat depot characterized by an increased infiltration of immune cells . A causal relationship between gut inflammation and mesenteric fat dysfunction (notably a relative expansion in size and an increase in expression of macrophages and immune factors) has been demonstrated in animal models of experimental colitis , . Impaired gut barrier function, along with gut inflammation, have also been observed in both genetic  and dietary ,  models of obesity.
Finally, there is an emerging body of literature demonstrating an association between altered gut microbiota profile and obesity in humans (see  and  for a recent review) which, from pioneering work on rodents , , , appears to be causative. The cross-linkage between gut microbiota, metabolic dysfunction and the immune system is best illustrated in Toll-like receptor-5 knockout mice which develop spontaneous colitis, insulin resistance, hyperlipidemia and increased visceral fat deposition . Importantly, all of these deleterious effects can be ameliorated by antibiotic administration, implicating gut microbiota change as causative and suggesting a feedback loop from the innate immune system to gut inflammation and microbiota profile.
Taken together the case can be made, see , that obesogenic diets induce gut dysfunction, which may lead to the stimulation of contiguous fat by an adverse microbial load and subsequently results in visceral fat inflammation and systemic metabolic dysregulation.
The aim of the present study, therefore, was to characterize the relationship between gut health, visceral fat dysfunction and metabolic dysregulation in diet-induced obese mice. We showed that a prolonged high saturated fat feeding induced inflammation and impaired barrier function in the gut which associated with specific alterations in microbiota profile. This, together with a distinct pro-inflammatory nature of the mesenteric fat contiguous with the gut but not of depots more remote, implicates the gut in the genesis of visceral adipose inflammation and systemic metabolic dysfunction.
All procedures were approved by the University of Sydney Animal Ethics Committee (approval number K00/2-2010/3/5225).
Female C57BL/6J mice were obtained from the Australian Animal Resources Centre (Perth, Australia), group-housed (2–4 mice per cage) and kept with regulated temperature (18–22°C) and humidity (∼50%) with a 12 h light/dark cycle. Starting at 16 weeks of age, the mice were fed either a control (10% kcal from fat) or a high saturated fat diet (HFD; 60% kcal from fat, of which 34% was saturated fat) ad libitum with free access to water for 8 or 12 weeks. For each mouse fresh stools (1 pellet per day) were collected on 3 consecutive days in the week before termination for gut microbiota profiling. At termination mice were anesthetized after a 4 h fast. Blood was taken by heart puncture and serum was stored at −80°C. After flushing with ice-cold bicarbonate buffer , segments of proximal colon (immediately below the cecum) were taken for assessment of gut permeability and gene expression (see below). Mesenteric, epididymal, perirenal and subcutaneous fat samples were taken for immunohistochemical staining and gene expression analysis, as was liver for the latter measurements.
Blood glucose was measured using a glucometer (Accu-Chek Performa, Roche, Mannheim, Germany). Serum concentrations of insulin, adiponectin and serum amyloid A3 were measured using assays from Millipore (Billerica, MA, USA). Liver was homogenized in isopropanol. Liver triglycerides and serum concentrations of alanine transaminase and triglycerides were measured using kits from Horiba ABX (Montpellier, France) and the assays were performed on the ABX Pentra 400 (Horiba ABX). Serum concentrations of interleukin (IL)-1β, IL-10, monocyte chemotactic protein (MCP)-1, tumor necrosis factor (TNF)-α, IL-6, IL-12p40 and plasminogen activator inhibitor (PAI)-1 were determined using commercially available cytokine kits and the xMAP® technology (Luminex Corporation, Austin, TX, USA). The data were analyzed with a four- or five-parametric curve fitting using the Bio-Plex Manager Software (version 5.0, Life Science Research, Hercules, CA, USA).
Assessment of gut permeability
Gut permeability was measured as described by Wang et al  with minor modifications. The segments of proximal colon for gut permeability measurement were opened along the mesenteric border and mounted in the Ussing chamber with an aperture of 0.3 cm2. The chamber was connected to a VCC MC6 amplifier, controlled and monitored using the Acquire & Analyze software (V2.3.177 Physiologic Instruments, San Diego, CA, USA). Experiments were carried out under current-clamp (open-circuit) conditions as described previously . Segments of colon were incubated in oxygenated (95% O2; 5% CO2) bicarbonate buffer at 37°C . Tissue was equilibrated for 15 min, thereafter a 3 µA current pulse was applied across the intestinal wall every 6 sec for 30 min. The transepithelial potential was measured and recorded by the Acquire & Analyze software, and the change in potential induced by the current pulse was used to calculate transepithelial resistance according to Ohm's Law.
Quantitative real-time PCR
RNA was extracted from homogenized tissue using TRI reagent (Sigma-Aldrich, St Louis, MO, USA) and isolated by phenol/chloroform extraction. Total RNA (200 ng) was reverse transcribed to cDNA using BioScript™ (Bioline, London, UK) and random hexamers (Applied Biosystems, Carlsbad, CA, USA). Primer sequences for sterol regulatory element binding protein (SREBP)-1c , peroxisome proliferator-activated receptor (PPAR)-γ , proglucagon , zona occludens (ZO)-1 , occludin  and IL-10  have been published elsewhere. Primers for SCD1, TNF-α and IL-6 were purchased from Qiagen (Valencia, CA, USA). mRNA expression was quantified by RT-qPCR using the Rotorgene™ 3000 Real Time Thermal Cycler (Qiagen). Fluorescence data were analyzed using the Rotor-Gene 6 software (version 6.0, Qiagen). mRNA expression was normalized to RPL-19 , UBC  and 18S rRNA  for colon, adipose tissue and liver respectively and reported as arbitrary units.
Fat samples were fixed in formalin overnight and embedded in paraffin. Sections of 10 µm thickness were treated with 10 µg/ml proteinase K (Sigma-Aldrich) at room temperature for antigen retrieval. Endogenous peroxidase and biotin signals were minimized using 0.3% (v/v) hydrogen peroxide and avidin/biotin block (Dako, Glostrup, Denmark) respectively. After incubating with 10% (v/v) normal horse serum to reduce non-specific staining, sections were incubated with purified anti-mouse F4/80 antibody (BioLegend, San Diego, CA, USA) for 1 h and subsequently with biotinylated rabbit anti-rat IgG antibody (Vector Laboratories, Burlingame, CA, USA) for 30 min at room temperature. The expression of F4/80 was detected using the VECTASTAIN® ABC Kit (Vector Laboratories) and the Liquid DAB+ Substrate Chromogen System (Dako). All sections were counterstained with hematoxylin. F4/80+ cells were quantified by counting the number of adipocytes and F4/80+ cells in 10 random areas at ×40 magnification and the abundance of F4/80+ cells was normalized to 100 adipocytes . Adipocyte size was determined by averaging the cross-sectional area of 5 adipocytes of each of the 10 selected ×40 magnification field using ImageJ (version 1.44p, National Institutes of Health, MD, USA).
Gut microbiota profiling
For each mouse three stool pellets (one per day) were pooled and homogenized in TE buffer (pH 7.5). DNA was extracted from 0.5 ml of homogenate using a bead beating method as described previously  and stored at −20°C. Metagenomic DNA (>500 ng from each mouse) was sent to Research and Testing Laboratories (Lubbock, USA) for bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) of the V6–V9 region of the 16S rDNA. Modified versions of primers F939 (5′TTGACGGGGGCCCGCAC3′) and R1492 (5′ATTAGATACCCNGGTAG3′) incorporating domains for 454 sequencing and unique identification tags were used to allow the identification of sequences from individual sample. Amplicons were sequenced on a GS Pico Titer Plate using the Roche 454 FLX instrument with corresponding FLX titanium reagents (Roche Applied Science, Indianapolis, IN, USA).
bTEFAP raw data were processed using Mothur  unless stated otherwise. Parameters used to filter sequences for analysis were based upon published studies , . Briefly, sequences from the raw 454 data were quality-filtered to exclude those with an average Phred score <30. Remaining sequence reads were binned into individual sample sets by the unique tags with sequences >200 nucleotides in length (excluding primers and tags) retained. The sequences were then screened to remove chimeras using chimera slayer within Mothur to give a final set of quality-filtered sequence reads for each sample. Taxonomic classifications were assigned using the naïve Bayesian algorithm with the Ribosomal Database Project (RDP) Training Set 6 as a reference database. No new data were generated from DNA sequencing. Nomenclature of all bacterial identification was based on Bergey's taxonomic outline. Within each sample the number of sequences for each bacterial taxonomic assignment is expressed as a percentage of the total reads retained after quality-filtering (relative abundance). To quantify the coverage and sampling effort of bTEFAP, RDP pyrosequencing pipeline was used to generate rarefaction curves of the sequences.
Data are expressed as means ± SEM. Student's t-test, one-way or two-way ANOVA were used to compare data from different treatment groups. Corrections of p-values for multiple testing were performed using Bonferroni post hoc tests. Relationships between selected outcome variables were examined by Pearson's correlation. Statistical analyses were performed using the GraphPad Prism Program (version 5.01, GraphPad Software Inc., San Diego, CA, USA). Significance was accepted at P<0.05.
High saturated fat diet induced weight gain, systemic insulin resistance and inflammation
By the end of the 8- and 12-week feeding protocols, the body weights of HFD mice were 22% and 36% higher respectively than animals fed the control diet (27.3±0.7 g vs 22.4±0.5 g for controls; P<0.001 at 8 weeks and 30.1±1.1 g vs 22.2±0.4 g for controls; P<0.001 at 12 weeks). Eight and 12 week results were not different for all other outcome variables and were therefore combined for analyses. HFD mice had a higher insulin/glucose ratio (1.4-fold; P = 0.020; insulin 91.1±8.8 pmol/l vs 56.8±6.8 pmol/l for controls; glucose 10.9±0.3 mmol/l vs 9.4±0.5 mmol/l for controls) as a marker of insulin resistance (Figure 1A). Circulating levels of the acute phase inflammatory marker serum amyloid A3 were 2.3-fold (P = 0.008; Figure 1B) higher in HFD mice, but in contrast, those of adiponectin were decreased by 36% (P = 0.011; Figure 1C). Serum concentrations of triglycerides, IL-1β, IL-10, MCP-1, TNF-α, IL-6, IL-12p40 and PAI-1 were not different between the diet groups (data not shown).
High saturated fat diet increased gut permeability and inflammation
In the proximal colon, transepithelial resistance of HFD mice was reduced by 38% (37.4±2.6 Ohm.cm2 vs 60.8±4.5 Ohm.cm2 for controls; P<0.001; Figure 2A) as compared to controls. mRNA expression of ZO-1 and proglucagon were also reduced by 40% (P = 0.025) and 28% (P = 0.104) respectively in HFD mice (Figure 2B), whereas the mRNA levels of occludin were not different between the diet groups (data not shown). The colon tissue of the HFD treatment group had increased mRNA expression of TNF-α by 6.6-fold (P = 0.037) but that of IL-6 was unchanged (Figure 3).
A: Transepithelial resistance of mouse proximal colon was determined in the Ussing chamber by measuring the change in potential difference in response to 3 µA current generated across the tissue segment. B: mRNA levels of zona occludens (ZO)-1 and proglucagon were measured using RT-qPCR. Gene expression was normalized to RPL-19. Open circles/bars = control; Closed circles/bars = HFD (n = 9–16 per group). Data are shown as mean ± SEM. ***P<0.001 and *P<0.05 compared to control.
High saturated fat diet altered gut microbiota profile
After quality-filtering a total of 246,694 sequences were obtained from 16 control and 16 HFD mice with a mean of 7,709 sequences per mouse (range 1,758–15,005; Table S1). The average number of reads for the control diet sample series was higher than that from HFD, however rarefaction analysis showed that taxonomic richness had plateaued in all samples at higher taxon level. Rarefaction curves at 95% sequence identity, considered to approximate genus level, showed that the rate of sampling was comparable across all samples and demonstrated sampling depth at this taxonomic resolution was comparable to previously reported studies (Figure S1) –. At the phylum level, HFD mice had more Firmicutes (73±1.5% vs 68±2.3% for controls; P = 0.041) and fewer Bacteroidetes (15±1.7% vs 19±1.3% for controls; P = 0.026) and thus a significantly higher Firmicutes: Bacteroidetes ratio (P = 0.019). HFD also induced significant shifts in fecal microbiota composition at the genus level of taxonomic resolution. Within members of the Firmicutes, notably there was a 75% decrease in Lactobacillus (P<0.001) and a 279% increase in Oscillibacter (P = 0.004) as compared to controls and these changes in abundance were closely associated with weight gain (Figure 4).
A: Relative abundance of main genera in fecal samples from control (open bars) and HFD (closed bars) mice (n = 16 per group). Data are shown as mean ± SEM. ***P<0.001, ** P<0.01 and *P<0.05 compared to control. Correlations between the abundance of Lactobacillus (B) and Oscillibacter (C) and weight changes. Gut microbiota profile was determined by metagenomic pyrosequencing from bacterial lineages in fecal samples.
Transepithelial resistance of the proximal colon was positively correlated with the abundance of Lactobacillus (r = 0.52; P = 0.013; Figure 5A) but negatively correlated with that of Oscillibacter (r = −0.55; P = 0.007; Figure 5B). Notably, increased Oscillibacter abundance was also associated with a reduction in the mRNA expression of ZO-1 (r = −0.37; P = 0.039; Figure 5C) and, although not statistically significant, a similar trend was observed with proglucagon (r = −0.34; P = 0.061; Figure 5D).
High saturated fat diet induced depot-specific inflammation and altered morphology in adipose tissue
Representative immunohistochemical staining of the macrophage marker F4/80 in adipose tissue of control and HFD mice is shown in Figure 6A. The abundance of macrophages (F4/80+ cells) was similar across all fat depots in the control mice. HFD increased macrophage infiltration in mesenteric (58%; P = 0.020) and epididymal (71%; P = 0.006) fat but was without effect in perirenal and subcutaneous fat (Figure 6B). HFD increased adipocyte size in mesenteric (80%; P<0.001), epididymal (57%; P = 0.008), perirenal (104%; P = 0.007) and subcutaneous (103%; P = 0.008) fat (Figure 6C). In both diet groups, mesenteric fat was the depot with the smallest adipocytes (Figure 6C).
A: Representative immunohistochemical staining of mesenteric (MES), epididymal (EPID), perirenal (PERI) and subcutaneous (SC) fat. Quantification of macrophage (F4/80+) infiltration (B) and adipocyte size (C). Tissues were fixed in formalin and embedded in paraffin. Sections were stained for F4/80 and counterstained with hematoxylin. Open bars = control; Closed bars = HFD (n = 4–10 per group). Data are shown as mean ± SEM. ***P<0.001, **P<0.01 and *P<0.05 compared to control.
Compared to controls, HFD induced a 2.5-fold increase in the mRNA levels of both TNF-α (P<0.001; Figure 7A) and IL-6 (P = 0.008; Figure 7B) in the mesenteric fat. This depot had by far the highest expression of TNF-α and IL-6 in mice fed the control diet, with expression levels being very low, and unaffected by HFD, in epididymal, perirenal and subcutaneous depots (Figures 7A and B). HFD had no effect on the mRNA expression of SREBP-1c and PPAR-γ in adipose tissue. In both diet groups, the highest expression of PPAR-γ (P<0.001; Figure 7C) and SREBP-1c (P = 0.003; Figure 7D) were found in mesenteric and epididymal fat respectively.
mRNA levels in control and high saturated fat diet (HFD) fed mice were measured by RT-qPCR. Gene expression was normalized to UBC. Open bars = control; Closed bars = HFD (n = 12–15 per group). Data are shown as mean ± SEM. ***P<0.001 and **P<0.01 compared to control. a, b, c: P<0.001, P<0.01 and P<0.05 respectively compared to other depots in the same diet group.
High saturated fat diet led to a pro-inflammatory and lipogenic liver
As shown in Figure 8A, HFD-fed mice tended to have higher expression of pro-inflammatory factors in the liver, as evidenced by the increased TNF-α (6.5-fold; P = 0.018) and IL-6 (2.2-fold; P = 0.137) mRNA expression. Hepatic SREBP-1c (6.4-fold; P<0.001) and SCD1 (1.7-fold; P = 0.069) mRNA levels were also trended to be elevated in HFD mice (Figure 8B).
mRNA levels of TNF-α, IL-6, SREBP-1c and SCD1 in control and high saturated fat diet (HFD) fed mice were measured using RT-qPCR. Gene expression was normalized to 18S. Open bars = control; Closed bars = HFD (n = 14–16 per group). Data are shown as mean ± SEM. ***P<0.001 and *P<0.05 compared to control.
The present study aimed to determine the effect of a high, predominantly saturated, fat diet (HFD) on gut health and its relationship with metabolic dysfunction. HFD mice exhibited systemic inflammation, whole-body insulin resistance and liver inflammation. We showed that HFD increased gut permeability and altered gut microbiota profile. Importantly, we demonstrated a relationship between gut barrier function and the abundance of specific genera of the microbial community. Together with the evidence of inflammation in the proximal colon and the distinct pro-inflammatory nature of the contiguous mesenteric, but not other fat depots, the present results highlight gut dysfunction as a salient feature of diet-induced metabolic dysregulation.
Our data suggest that HFD initiates metabolic changes that impaired gut barrier function, as evidenced both by the decrease in transepithelial resistance and mRNA expression of ZO-1 in the proximal colon. Similar outcomes for other obesogenic diets on gut barrier function have also been reported. Cani et al  showed an increase in whole-gut permeability in HFD mice, an effect associated with a reduction in mRNA expression of tight-junction proteins including ZO-1. Little is known, however, about the barrier integrity of functionally distinct regions of the intestine in diet-induced models of obesity. The present study focused directly on the proximal colon, which is the part of the gut predicted to have the most intense microbial activity. Accordingly, loss of barrier integrity in the proximal colon has the potential to induce a disproportionate effect of gut microbiota on systemic metabolism.
The increased permeability of the proximal colon is postulated to participate in a feedback loop with inflammatory processes. In our study, and others using obesogenic diets, mice in the experimental groups had increased TNF-α mRNA expression  in the intestine. In an experimental model of colitis, the progressive increase in colonic permeability is associated with a corresponding reduction in ZO-1 protein expression . There is also some evidence suggesting a direct effect of TNF-α on gut barrier integrity. Anti-TNF-α treatment improves gut barrier function in patients with Crohn's disease . In Caco-2 cell cultures, TNF-α reduced transepithelial resistance and ZO-1 protein expression via a NFκB-dependent pathway . The effect of TNF-α on NFκB activation also increased the expression and activity of myosin light chain kinase, which subsequently leads to disorganization of tight-junction proteins at the intestinal barrier . It is worth noting that other cytokines upstream of NFκB, including IL-1β  and IFN-γ , also have been shown to decrease tight-junction function. The collective role of inflammatory pathways, rather than individual cytokines, therefore, appears to be critical in the regulation of gut barrier function.
The activity of the microbiota is a major determinant of gut health and a ‘poor’ microbiota composition has been linked to obesity and metabolic dysfunction . The shift in the ratio of Firmicutes and Bacteroidetes by obesogenic diets has been frequently reported, but not universally so. Here we observed a small, but significant shift towards an increased Firmicutes: Bacteroidetes ratio in the HFD mice. The most startling microbiota changes were observed within the Firmicutes, with a very strong association between changes in relative abundance of Lactobacillus and Oscillibacter and the two diet groups. Members of the genus Lactobacillus have been intensively investigated for probiotic properties and several strains have been shown to ameliorate gut inflammation  and enhance barrier function  in experimental models of gut dysfunction. A novel finding here is the positive correlation between the abundance of the indigenous Lactobacillus community (i.e. not administered probiotic strains) and barrier function of the proximal colon. However we did not observe a significant correlation between Lactobacillus content and mRNA expression of tight-junction proteins. The effect of probiotic Lactobacillus strains on tight-junction integrity is not entirely clear and appears to be strain-specific , . In humans, administration of L. plantarum promoted localization of ZO-1 and occludin in the tight-junctions without necessarily affecting their transcriptional levels . It is worth noting that the beneficial effect of Lactobacillus on gut health may not be restricted to the maintenance of barrier integrity, as there is some evidence suggesting that certain strains may alter the expression of defensin, an anti-microbial peptide, which is important for mucosal protection , .
The present study identified Oscillibacter-like organisms as a potentially important gut microbe that mediates HFD-induced gut dysfunction. This group, including Oscillibacter and Oscillospira, are very poorly represented in culture collections but have been consistently detected in the microbial community of humans , . Recent data suggest that the abundance of Oscillibacter is diet-responsive in obese individuals  but to date little is known about its physiological role. The negative correlation between the abundance of Oscillibacter and parameters of barrier function in the proximal colon is intriguing. There is some in vitro evidence suggesting that metabolites from other gut microbes may modify the abundance of certain strains of Oscillibacter . It is possible that Oscillibacter directly regulates components involved in the maintenance of gut barrier integrity, or its relationship with gut permeability may be a secondary effect consequent upon alterations in the overall composition of the microbial community. Characterization of the metabolic effect of Oscillibacter as well as its interactions with other microbes would be critical to elucidate its role in diet-induced metabolic dysfunctions.
We identified mesenteric fat as a metabolically distinct visceral fat depot with the most prominent pro-inflammatory nature. Our data showed that mesenteric fat has the highest mRNA expression of PPAR-γ and the smallest adipocyte size. This is in contrast to epididymal fat which had the biggest adipocytes and the highest mRNA content of SREBP-1c, a transcription factor that promotes lipogenesis. HFD mice had increased expression of TNF-α and IL-6 and macrophage infiltration in mesenteric fat ,  and the role of TNF-α in the systemic dysmetabolism may be particularly critical . Similar trends of depot-specific differences in the expression of pro-inflammatory cytokines have been reported previously in animal models of high-fat feeding , .
A range of non-adipocytes cells are known to contribute strongly to the pro-inflammatory secretory profile of adipose tissue . Interestingly, the HFD-induced increase in macrophage infiltration was similar in mesenteric and epididymal fat, and yet only the former had a distinctly elevated expression of pro-inflammatory cytokines. A limitation of our study is that we used only F4/80 as a macrophage marker, which did not allow us to distinguish sub-populations of macrophages. The increased transcriptional expression of pro-inflammatory factors in the mesenteric fat may be a consequence of the preferential infiltration of macrophages with a pro-inflammatory phenotype . Equally, the presence of lymph nodes in mesenteric , but not epididymal, fat implies that immune cells other than macrophages, e.g. B-cells, T-cells and Natural Killer cells, are likely to contribute to the secretory function of the mesenteric depot.
The increased macrophage infiltration and TNF-α expression in mesenteric fat of our HFD mice is consistent with results in rats with induced gut inflammation  and is likely to be a consequence of the ‘leakage’ of gut luminal content. Cenac et al  demonstrated the sequential occurrences of gut inflammation, impaired barrier function and bacterial translocation to the mesenteric lymph nodes in an experimental model of colitis. Similar metabolic sequelae of gut inflammation in obesity are yet to be reported. However, the recent report of bacterial translocation into the mesenteric fat of HFD mice  and of elevated circulating endotoxin levels in animal models of diet-induced obesity  and in obese and type 2 diabetic patients related to insulin resistance ,  are consistent with our hypothesized role of the gut in metabolic dysfunction .
Mechanistic studies will be an important extension of the current work. We, and others, have shown that an obesogenic diet can induce gut dysfunction involving multiple feedbacks with immune and metabolic regulation. It remains unclear whether HFD-induced gut dysfunction is a specific effect of fatty acid subtype (e.g. saturated fatty acids are known to be pro-inflammatory) or is merely a consequence of energy overload. Elucidating the sequence of factors that initiates gut dysfunction will be important for the maintenance of optimal metabolic health. From the disease treatment perspective, the interactions and feedback mechanisms between the innate immune system and the microbiota profile and their effect on metabolic outcomes  imply that a combination of pharmaceutical interventions of immunomodulators (e.g. pro-resolving mediators that are critical in maintaining immunological homeostasis of mucosal surface ) and manipulation of microbiota (e.g. dietary supplementation of prebiotics, probiotics and resistant starches) may be novel gut-targeted approaches to ameliorate metabolic dysfunctions.
In summary, the current findings build on a literature now becoming compelling that the gut is a central player in the aetiology of diet-induced metabolic diseases.
Rarefaction curves at 90% (A) and 95% (B) sequence identity depicting the number of operational taxonomic units (OTUs) against sampling effort (n = 16 per group). Curves were generated based on the pool of 246,694 high quality sequences. The number of OTUs present in individual samples was sorted by control (C) and high-fat diet (F).
The authors appreciate the assistance of Dr Jane Radford, Shanna Trollip and Jenny Hoffmann with immunohistochemical staining; Dr Helen Ball, Dr Dale Hancock and Luxi Meng with RT-qPCR; and Charlotte Lindgren, Anne-Cristine Carlsson, Lena Amrot Fors and Maria Ericsson with serum assays.
Conceived and designed the experiments: YYL CRC AJM AD DIC NHH IDC AJH LHS JO. Performed the experiments: YYL CWYH JO LHS. Analyzed the data: YYL CWYH AJH. Contributed reagents/materials/analysis tools: YYL CRC AD JO DIC NHH AJH LHS. Wrote the paper: YYL CWYH CRC AJM AD JO DIC NHH IDC LHS.
- 1. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, et al. (2002) Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283: E1135–1143.
- 2. Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, et al. (2009) Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 32: 932–937.
- 3. Barbarroja N, Lopez-Pedrera R, Mayas MD, Garcia-Fuentes E, Garrido-Sanchez L, et al. (2010) The obese healthy paradox: is inflammation the answer? Biochem J 430: 141–149.
- 4. Lam YY, Janovska A, McAinch AJ, Belobrajdic DP, Hatzinikolas G, et al. (2011) The use of adipose tissue-conditioned media to demonstrate the differential effects of fat depots on insulin-stimulated glucose uptake in a skeletal muscle cell line. Obes Res Clin Pract 5: e43–e54.
- 5. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW (2004) Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145: 2273–2282.
- 6. Fain JN (2010) Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm 2010: 513948.
- 7. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, et al. (2006) Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55: 1554–1561.
- 8. Bertin B, Desreumaux P, Dubuquoy L (2010) Obesity, visceral fat and Crohn's disease. Curr Opin Clin Nutr Metab Care 13: 574–580.
- 9. Thomaz MA, Acedo SC, de Oliveira CC, Pereira JA, Priolli DG, et al. (2009) Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. Pharmacol Res 60: 341–346.
- 10. Gambero A, Marostica M, Abdalla Saad MJ, Pedrazzoli J Jr (2007) Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis 13: 1357–1364.
- 11. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, et al. (2007) Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292: G518–525.
- 12. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470–1481.
- 13. Li H, Lelliott C, Hakansson P, Ploj K, Tuneld A, et al. (2008) Intestinal, adipose, and liver inflammation in diet-induced obese mice. Metabolism 57: 1704–1710.
- 14. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, et al. (2009) A core gut microbiome in obese and lean twins. Nature 457: 480–484.
- 15. Diamant M, Blaak EE, de Vos WM (2011) Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 12: 272–281.
- 16. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, et al. (2008) Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 22: 2416–2426.
- 17. Backhed F, Manchester JK, Semenkovich CF, Gordon JI (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 104: 979–984.
- 18. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, et al. (2010) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328: 228–231.
- 19. Lam YY, Mitchell AJ, Holmes AJ, Denyer GS, Gummesson A, et al. (2011) Role of the gut in visceral fat inflammation and metabolic disorders. Obesity (Silver Spring) 19: 2113–2120.
- 20. Gelbmann CM, Schteingart CD, Thompson SM, Hofmann AF, Barrett KE (1995) Mast cells and histamine contribute to bile acid-stimulated secretion in the mouse colon. J Clin Invest 95: 2831–2839.
- 21. Wang Q, Fang CH, Hasselgren PO (2001) Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol Regul Integr Comp Physiol 281: R1013–1023.
- 22. Lee IH, Dinudom A, Sanchez-Perez A, Kumar S, Cook DI (2007) Akt mediates the effect of insulin on epithelial sodium channels by inhibiting Nedd4-2. J Biol Chem 282: 29866–29873.
- 23. Pachikian BD, Neyrinck AM, Cani PD, Portois L, Deldicque L, et al. (2008) Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol 8: 21.
- 24. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58: 1091–1103.
- 25. Holmes JL, Van Itallie CM, Rasmussen JE, Anderson JM (2006) Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns. Gene Expr Patterns 6: 581–588.
- 26. Volynets V, Spruss A, Kanuri G, Wagnerberger S, Bischoff SC, et al. (2010) Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. J Lipid Res 51: 3414–3424.
- 27. Li P, Lu M, Nguyen MT, Bae EJ, Chapman J, et al. (2010) Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J Biol Chem 285: 15333–15345.
- 28. Zeyda M, Gollinger K, Kriehuber E, Kiefer FW, Neuhofer A, et al. (2010) Newly identified adipose tissue macrophage populations in obesity with distinct chemokine and chemokine receptor expression. Int J Obes (Lond) 34: 1684–1694.
- 29. Sachithanandan N, Fam BC, Fynch S, Dzamko N, Watt MJ, et al. (2010) Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity. Hepatology 52: 1632–1642.
- 30. Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, et al. (2009) Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 94: 4619–4623.
- 31. Thompson CL, Wang B, Holmes AJ (2008) The immediate environment during postnatal development has long-term impact on gut community structure in pigs. ISME J 2: 739–748.
- 32. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, et al. (2009) Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75: 7537–7541.
- 33. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, et al. (2009) Bacterial community variation in human body habitats across space and time. Science 326: 1694–1697.
- 34. Kumar PS, Brooker MR, Dowd SE, Camerlengo T (2011) Target region selection is a critical determinant of community fingerprints generated by 16S pyrosequencing. PLoS One 6: e20956.
- 35. Dowd SE, Sun Y, Wolcott RD, Domingo A, Carroll JA (2008) Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) for microbiome studies: bacterial diversity in the ileum of newly weaned Salmonella-infected pigs. Foodborne Pathog Dis 5: 459–472.
- 36. Huse SM, Dethlefsen L, Huber JA, Mark Welch D, Relman DA, et al. (2008) Exploring microbial diversity and taxonomy using SSU rRNA hypervariable tag sequencing. PLoS Genet 4: e1000255.
- 37. Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, et al. (2010) High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 5: e12191.
- 38. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, et al. (2007) Loss of the Tight Junction Protein ZO-1 in Dextran Sulfate Sodium Induced Colitis. Journal of Surgical Research 140: 12–19.
- 39. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, et al. (2002) Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97: 2000–2004.
- 40. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, et al. (2004) TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation. American Journal of Physiology - Gastrointestinal and Liver Physiology 286: G367–G376.
- 41. Ye D, Ma I, Ma TY (2006) Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 290: G496–504.
- 42. Al-Sadi R, Ye D, Said HM, Ma TY (2010) IL-1[beta]-Induced Increase in Intestinal Epithelial Tight Junction Permeability Is Mediated by MEKK-1 Activation of Canonical NF-[kappa]B Pathway. The American Journal of Pathology 177: 2310–2322.
- 43. Youakim A, Ahdieh M (1999) Interferon-γ decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. American Journal of Physiology - Gastrointestinal and Liver Physiology 276: G1279–G1288.
- 44. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, et al. (2010) The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 53: 606–613.
- 45. Xia Y, Chen H-Q, Zhang M, Jiang Y-Q, Hang X-M, et al. (2011) Effect of Lactobacillus plantarum LP-Onlly on gut flora and colitis in interleukin-10 knockout mice. Journal of Gastroenterology and Hepatology 26: 405–411.
- 46. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, et al. (2009) Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 43: 163–172.
- 47. Anderson RC, Cookson AL, McNabb WC, Park Z, McCann MJ, et al. (2010) Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol 10: 316.
- 48. Oliveira M, Bosco N, Perruisseau G, Nicolas J, Segura-Roggero I, et al. (2011) Lactobacillus paracasei Reduces Intestinal Inflammation in Adoptive Transfer Mouse Model of Experimental Colitis. Clin Dev Immunol 2011: 807483.
- 49. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, et al. (2010) Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 298: G851–859.
- 50. Schlee M, Harder J, Koten B, Stange EF, Wehkamp J, et al. (2008) Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 151: 528–535.
- 51. Paolillo R, Romano Carratelli C, Sorrentino S, Mazzola N, Rizzo A (2009) Immunomodulatory effects of Lactobacillus plantarum on human colon cancer cells. International Immunopharmacology 9: 1265–1271.
- 52. Mondot S, Kang S, Furet JP, Aguirre de Carcer D, McSweeney C, et al. (2011) Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm Bowel Dis 17: 185–192.
- 53. Claesson MJ, O'Sullivan O, Wang Q, Nikkila J, Marchesi JR, et al. (2009) Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One 4: e6669.
- 54. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, et al. (2011) Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 5: 220–230.
- 55. Salazar N, Gueimonde M, Hernandez-Barranco AM, Ruas-Madiedo P, de los Reyes-Gavilan CG (2008) Exopolysaccharides produced by intestinal Bifidobacterium strains act as fermentable substrates for human intestinal bacteria. Appl Environ Microbiol 74: 4737–4745.
- 56. Terra X, Pallarés V, Ardèvol A, Bladé C, Fernández-Larrea J, et al. (2011) Modulatory effect of grape-seed procyanidins on local and systemic inflammation in diet-induced obesity rats. The Journal of Nutritional Biochemistry 22: 380–387.
- 57. Cawthorn WP, Sethi JK (2008) TNF-alpha and adipocyte biology. FEBS Lett 582: 117–131.
- 58. Adapala VJ, Buhman KK, Ajuwon KM (2011) Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet. J Inflamm (Lond) 8: 5.
- 59. Kim OY, Lee SM, Do H, Moon J, Lee KH, et al. (2011) Influence of Quercetin-rich Onion Peel Extracts on Adipokine Expression in the Visceral Adipose Tissue of Rats. Phytother Res.
- 60. Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175–184.
- 61. Pond CM (2005) Adipose tissue and the immune system. Prostaglandins Leukot Essent Fatty Acids 73: 17–30.
- 62. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, et al. (2002) Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 161: 1903–1915.
- 63. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, et al. (2011) Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 3: 559–572.
- 64. Lassenius MI, Pietilainen KH, Kaartinen K, Pussinen PJ, Syrjanen J, et al. (2011) Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 34: 1809–1815.
- 65. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, et al. (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292: E740–747.
- 66. Campbell EL, Serhan CN, Colgan SP (2011) Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. J Immunol 187: 3475–3481.